{"id":78777,"date":"2026-09-04T16:25:28","date_gmt":"2026-09-04T08:25:28","guid":{"rendered":"https:\/\/flcube.com\/?p=78777"},"modified":"2026-09-04T16:25:29","modified_gmt":"2026-09-04T08:25:29","slug":"yipinhongs-ar882-meets-primary-endpoint-in-phase-3-gout-trial-outperforming-febuxostat-on-uric-acid-reduction","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=78777","title":{"rendered":"Yipinhong\u2019s AR882 Meets Primary Endpoint in Phase 3 Gout Trial, Outperforming Febuxostat on Uric Acid Reduction"},"content":{"rendered":"\n

Yipinhong Pharmacy Group Co., Ltd (SHE: 300723<\/a>)<\/strong> announced that its Phase 3 trial<\/strong> for the Category 1 drug AR882 (Pozdeutinurad)<\/strong> in patients with gout and hyperuricemia<\/strong> has met its primary endpoint. In a 683-participant study, the AR882 75mg group achieved significantly superior serum uric acid (sUA) reduction versus febuxostat<\/strong> at 24 weeks \u2014 a pivotal validation for the next-generation URAT1 inhibitor<\/strong> that could redefine treatment standards in one of China\u2019s most prevalent metabolic diseases.<\/p>\n\n\n\n

Trial Overview<\/h2>\n\n\n\n
Item<\/th>Detail<\/th><\/tr><\/thead>
Sponsor<\/td>Yipinhong Pharmacy Group Co., Ltd (SHE: 300723)<\/strong><\/td><\/tr>
Product<\/td>AR882 (Pozdeutinurad)<\/strong>, Category 1 drug<\/td><\/tr>
Study Design<\/td>Phase 3, active-controlled<\/td><\/tr>
Comparator<\/td>Febuxostat 40mg<\/strong><\/td><\/tr>
Population<\/td>Patients with gout and hyperuricemia<\/strong><\/td><\/tr>
Enrollment<\/td>683 participants<\/td><\/tr>
Primary Endpoint<\/td>Met (P<0.001)<\/td><\/tr>
Date<\/td>03 Sept 2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Clinical Evidence \u2013 Phase 3 Results<\/h2>\n\n\n\n
Endpoint<\/th>AR882 75mg (24 Weeks)<\/th>Statistical Significance<\/th><\/tr><\/thead>
Primary:<\/strong> sUA <360 \u03bcmol\/L<\/td>86.0%<\/strong><\/td>Superior to febuxostat 40mg (P<0.001)<\/td><\/tr>
Key secondary:<\/strong> sUA <300 \u03bcmol\/L<\/td>71.3%<\/strong><\/td>Superior to febuxostat (P<0.001)<\/td><\/tr>
Key secondary:<\/strong> sUA <240 \u03bcmol\/L<\/td>50.3%<\/strong><\/td>Superior to febuxostat (P<0.001)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

The Phase 3 results demonstrate that AR882<\/strong> 75mg not only met its prespecified primary efficacy endpoint with statistically significant superiority over the active comparator, but also delivered robust responses at the more stringent secondary thresholds of sUA <300 \u03bcmol\/L and <240 \u03bcmol\/L \u2014 levels associated with crystal dissolution and long-term disease control. Importantly, AR882<\/strong> demonstrated a favorable safety and tolerability profile<\/strong>, a critical factor for a chronic urate-lowering therapy.<\/p>\n\n\n\n

Drug Profile & Mechanism of Action<\/h2>\n\n\n\n